{"id":2925,"date":"2018-07-19T13:18:25","date_gmt":"2018-07-19T17:18:25","guid":{"rendered":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/intracellular-delivery-of-antibodies-and-peptides-using-a-peptide-based-technology\/"},"modified":"2024-09-03T10:02:40","modified_gmt":"2024-09-03T14:02:40","slug":"intracellular-delivery-of-antibodies-and-peptides-using-a-peptide-based-technology","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/intracellular-delivery-of-antibodies-and-peptides-using-a-peptide-based-technology\/","title":{"rendered":"Intracellular delivery of antibodies and peptides using a peptide-based technology"},"content":{"rendered":"\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle\"><strong>Principal Investigator:<\/strong><\/p>\n\n\n\n<p><strong>Fr\u00e9d\u00e9ric Calon<\/strong><br>Universit\u00e9 Laval<br><strong>Fr\u00e9d\u00e9ric Couture<\/strong><br>TransBIOTech<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle\"><strong>Co-investigators<\/strong><\/p>\n\n\n\n<p><strong>David Guay<\/strong><br>Feldan Therapeutics<\/p>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><strong><strong><strong><strong>Completed Project<\/strong><\/strong><\/strong><\/strong><\/strong> of <strong><strong><strong>$1,241,474 over 2 years<\/strong><\/strong><\/strong><\/h2>\n\n\n\n<ul class=\"is-style-checkmark wp-block-list\">\n<li><strong><strong>Supported by CQDM through:<\/strong><\/strong> \n<ul class=\"wp-block-list\">\n<li>Amgen<\/li>\n\n\n\n<li>Takeda<\/li>\n\n\n\n<li>GlaxoSmithKline<\/li>\n\n\n\n<li>Sanofi-Aventis<\/li>\n\n\n\n<li>Janssen<\/li>\n\n\n\n<li>MEI<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong><strong>And by a co-funding partner:<\/strong><\/strong>\n<ul class=\"wp-block-list\">\n<li>Feldan Therapeutics<\/li>\n\n\n\n<li>Mitacs<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Challenge<\/h2>\n\n\n\n<p>The popularity of therapeutic proteins has recently increased mostly due to their broad applicability, but the druggable space for biologics is still restricted to extracellular targets. Indeed, the number of potential targets either secreted or with extracellular domains represents only one-third of the proteome, thus significantly restricting attainable pathways. In parallel, intracellular delivery methods are still plagued by inefficiency and limited applicability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><strong>Solution<\/strong><\/strong><\/h2>\n\n\n\n<p>Feldan Therapeutics developed the Feldan Shuttle, a platform allowing the delivery of biologics\u00a0<em>in vivo<\/em>. The Feldan Shuttle is a new peptide family with specific properties including cell membrane permeability to allow the intracellular delivery of active and functional proteins in different organs. In collaboration with Universit\u00e9 Laval, the main objective of the project was to study the ability of the platform to deliver intrabodies (intracellular antibodies) and potentially therapeutic peptides inside cells\u00a0<em>ex vivo<\/em>\u00a0and then\u00a0<em>in vivo<\/em>. The Feldan Shuttle made very significant progress during the project, by optimizing the platform peptides and demonstrating their stability, resistance to hostile environment, fast and efficient biodistribution of functional cargos, and innocuity after repeated administration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A<strong>chievements\/Impact<\/strong><\/h2>\n\n\n\n<p>Within two years only, the Feldan Shuttle technology acquired features critical for\u00a0<em>in vivo<\/em>\u00a0application of its platform to deliver therapeutic compounds intracellularly. The needs of pharmaceutical industry were better comprehended thanks to CQDM\u2019s mentorship program with the active participation of five large industry members. \u00a0Feldan Therapeutics expanded its qualified staff and is now ready to bring the peptide-based delivery technology to the clinical stage.<\/p>\n","protected":false},"featured_media":3823,"template":"","project-category":[97],"class_list":["post-2925","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-biological-and-therapeutic"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/2925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3823"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2925"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=2925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}